1-2 of 2
Michael Pacini, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease

Robert E Molokie, MD, Donald Lavelle, PhD, Michel Gowhari, DO, Michael Pacini, PharmD, Lani Krauz, Johara Hassan, MD, Vinzon Ibanez, Maria A Ruiz, Daisy Pacelli, Sherry Fada, Mitch A. Phelps, PhD, Santosh L. Saraf, MD, Lewis L. Hsu, MD PhD, Victor R. Gordeuk, MD, Joseph DeSimone, PhD, Yogenthiran Saunthararajah, MD
Journal: Blood
Blood (2016) 128 (22): 124.
https://doi.org/10.1182/blood.V128.22.124.124
Published: 2016
Journal Articles

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

Donald Lavelle, PhD, Michel Gowhari, DO, Michael Pacini, PharmD, Lani Krauz, RN, Johara Hassan, MD, Vinzon Ibanez, Maria A. Ruiz, MSc, Daisy Pacelli, BSc, Chaher Alhandalous, MD, Mitch A. Phelps, PhD, Kathleen Fenner, BS,MS, Reda Z. Mahfouz, MDPhD, John Barnard, Lewis L. Hsu, MD PhD, Victor R. Gordeuk, MD, Joseph DeSimone, PhD, Yogen Saunthararajah, MD, Robert E. Molokie, MD
Journal: Blood
Blood (2014) 124 (21): 90.
https://doi.org/10.1182/blood.V124.21.90.90
Published: 2014